Pang Kun, Li Mei-Li, Hao Lin, Shi Zhen-Duo, Feng Harry, Chen Bo, Ma Yu-Yang, Xu Hao, Pan Deng, Chen Zhe-Sheng, Han Cong-Hui
Department of Urology, Xuzhou Central Hospital, Affiliated Central Hospital of Xuzhou Medical University, Xuzhou, China.
Department of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Xuzhou, China.
Front Oncol. 2022 May 23;12:900496. doi: 10.3389/fonc.2022.900496. eCollection 2022.
Cancer is a major public health problem worldwide. Studies on oncogenes and tumor-targeted therapies have become an important part of cancer treatment development. In this review, we summarize and systematically introduce the gene enhancer of rudimentary homolog (ERH), which encodes a highly conserved small molecule protein. ERH mainly exists as a protein partner in human cells. It is involved in pyrimidine metabolism and protein complexes, acts as a transcriptional repressor, and participates in cell cycle regulation. Moreover, it is involved in DNA damage repair, mRNA splicing, the process of microRNA hairpins as well as erythroid differentiation. There are many related studies on the role of ERH in cancer cells; however, there are none on tumor-targeted therapeutic drugs or related therapies based on the expression of ERH. This study will provide possible directions for oncologists to further their research studies in this field.
癌症是全球主要的公共卫生问题。对癌基因和肿瘤靶向治疗的研究已成为癌症治疗发展的重要组成部分。在本综述中，我们总结并系统介绍了原始同源基因增强子（ERH），它编码一种高度保守的小分子蛋白。ERH在人类细胞中主要作为一种蛋白伴侣存在。它参与嘧啶代谢和蛋白质复合物，作为转录抑制因子，并参与细胞周期调控。此外，它还参与DNA损伤修复、mRNA剪接、微小RNA发夹结构的形成以及红细胞分化。关于ERH在癌细胞中的作用有许多相关研究；然而，基于ERH表达的肿瘤靶向治疗药物或相关疗法却尚无研究。本研究将为肿瘤学家在该领域的进一步研究提供可能的方向。
